Method for subtyping lymphoma types by means of expression profiling
US10607717B2 · kind B2 · utility
2Cited by
43References
3Claims
0Family size
Assignees
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- British Columbia Cancer Agency Branch
- Arizona Board of Regents on Behalf of the University of Arizona
- UNIVERSITAT DE BARCELONA
- HOSPITAL CLÍNIC DE BARCELONA
- The Cleveland Clinic Foundation
- BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
- Oregon Health & Science University
- Julius-Maximilians-Universitat Wurzburg
- Oslo University Hospital HF
Inventors
- Louis M. Staudt
- George W. Wright
- David William Scott
- Joseph M. Connors
- Randy D. Gascoyne
- Lisa M. Rimsza
- Elias Campo Guerri
- Raymond Tubbs
- Timothy C. Greiner
- James Robert Cook
- Kai Fu
- Paul Michael Williams
- Chih-Jian Lih
- Elaine S. Jaffe
- Rita M. Braziel
- Andreas Rosenwald
- Erlend B. Smeland
- Wing C. Chan
- German Ott
- Jan Delabie
- Dennis Weisenburger
Key dates
| Filing date | Nov 5, 2014 |
| Grant date | Mar 31, 2020 |
| Priority date | — |
| Expiry date | Oct 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/166
- WIPO fieldComputer technology
- WIPO sectorElectrical engineering
Abstract
The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.